Pfizer and Odyssey Thera Expand Cell-Based Drug-Profiling Collaboration | GenomeWeb
NEW YORK (GenomeWeb News) – Pfizer will use Odyssey Thera’s cell-based protein-fragment complementation assay (PCA) technology to evaluate the selectivity of Pfizer compounds, Odyssey said today.
 
Under the terms of the agreement, Odyssey will receive an upfront payment, research and capital expenditure funding, and success-based milestone payments. Further financial details were not disclosed.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.